Clinical significance of cystatin C in early diagnosis and treatment of renal damage of multiple myeloma
Li Bihui
Abstract：Objective To investigate clinical significance of cystatin C in early diagnosis and treatment of renal damage in patients with multiple myeloma.Methods From January 2012 to March 2016,127 patients diagnosed of multiple myeloma in the Affiliated Hospital of Guilin Medical University were enrolled as observation group;54 healthy people were enrolled as control group.According to Durie-Salmon (DS) staging criterion and renal damage,the observation group was subdivided into group A [DS stage Ⅰ,renal function lightly damaged,endogenous creatinine clearance rate (Ccr) ≥ 75 ml/min,19 cases],group B (DS stage Ⅱ,renal function decreased,50 ml/min ＜ Ccr ＜ 75 ml/min,44 cases) and group C (DS stage Ⅲ,renal function insufficiency,25 ml/min ＜ Ccr≤50 ml/min,64 cases).In observation group,50 patients had BD chemotherapy and 77 patients had VAD chemotherapy.Serum levels of serum cystatin C,creatinine and urea were analyzed before treatment and after 2,4,6 cycles of treatment.Results The serum level of cystatin C in group A[(1.01 ± 0.23) mg/L] was significantly higher than that in control group before treatment;serum levels of cystatin C,creatinine,urea in group B,C were significantly higher than those in control group before treatment [(1.52 ± 0.35),(1.88 ± 0.75) mg/L vs (0.73 ± 0.14) mg/L;(142 ± 20),(282 ± 51) μmol/L vs (62 ± 22) μmol/L;(8.4 ± 1.9),(11.2 ± 2.0) mmol/L vs (3.5 ± 2.3) mmol/L] and the levels in group B were significantly higher than those in group C (P ＜ 0.05).In 50 patients with BD chemotherapy,the serum level of cystatin C after 2 cycles of treatment [(1.39 ± 0.39)mg/L] was significantly lower than that before treatment;serum levels of cystatin C,urea,creatinine after 4,6 cycles of treatment were significantly lower than those before treatment [(1.01 ± 0.29),(0.88 ± 0.21)mg/L vs (1.63 ± 0.48)mg/L;(103 ± 19),(62 ± 16) μmol/L vs (162 ± 28) μmol/L;(6.2 ± 1.7),(5.2 ± 1.6) mmol/L vs (9.3 ± 2.0) mmol/L] (P ＜ 0.05).In 77 patients with VAD chemotherapy,serum levels of cystatin C,urea after 2 cycles of treatment [(1.44 ± 0.45) mg/L,(8.4 ± 2.0) mmol/L] were significantly lower than those before treatment;serum levels of cystatin C,urea,creatinine after 4,6 cycles of treatment were significantly lower than those before treatment [(1.32 ± 0.34),(1.09 ± 0.27) mg/L vs (1.62 ± 0.48) mg/L;(130 ±22),(77 ± 18) μmol/L vs (160 ±28) μmol/L;(7.3 ± 1.8),(6.1 ± 1.8) mmol/L vs (9.3 ±2.1) mmol/L] (P ＜ 0.05).Conclusion Cystatin C is more sensitive in early diagnosis of renal damage and assessment of renal function recovery compared to creatinine and urea in myeloma nephropathy.
Keywords：Multiple myelomaMyeloma nephropathyCystatin C
Publication Date：2017-03-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 382-386 )